__25J148Qli3.jpg)
我們使用 Cookie 以允許我們網站的正常工作、個性化設計內容和廣告、提供社交媒體功能並分析流量。我們還同社交媒體、廣告和分析合作夥伴分享有關您使用我們網站的信息
19
Aug 2025
Performance
ScinoPharm Taiwan Continues Strategic Expansion in Formulation and CDMO Businesses
ScinoPharm Taiwan (Stock Code: 1789) held an online investor conference today to report its financial results for the first half of 2025. The company recorded consolidated revenue of US$45.2 million, equivalent to NT$1.434 billion, and a net profit after tax of NT$80 million.
Read More
15
Mar 2025
Performance
ScinoPharm Taiwan Maintains Stable Operations, Actively Expands into Formulation Development and CDMO Business
ScinoPharm Taiwan (Stock Code: 1789) held an investor conference today to report on its 2024 operational performance and business developments. The company achieved a consolidated annual revenue of NT$3.406 billion, marking a moderate 7% growth. Net profit after tax reached NT$339 million, reflecting an 18% year-over-year increase, with earnings per share (EPS) rising to NT$0.43.
Read More